Öykü Arslan

Öykü Arslan

Auto-generated profile, based on publicly available information

Öykü Arslan

Çam ve Sakura City Hospital, Department of Hematology, Istanbul, TR

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2018 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
BABurak Arslan
Burak Arslan
OGOkan Gürkan
Okan Gürkan
BÇBuğra Çetin
Buğra Çetin
ÖAÖykü Aksoy Arslan
Öykü Aksoy Arslan
TGTaha Göv
Taha Göv
EOEnver Ozdemir
Enver Ozdemir

27 August 2021 in Journal of Academic Research in Medicine
Verified
Journal Article
Closed access
NÇNusret Can Çilesiz
Nusret Can Çilesiz
BABurak Arslan
Burak Arslan
MBMustafa Bahadır Can Balcı
Mustafa Bahadır Can Balcı
ÖAÖykü Arslan
Öykü Arslan
BNBarış Nuhoğlu
Barış Nuhoğlu

29 January 2022 in Medical Science and Discovery
Verified
Journal Article
Open access
PDF file
ETEmine Türkkan
Emine Türkkan
GÖGül Nihal Özdemir
Gül Nihal Özdemir
ÖAÖykü Arslan
Öykü Arslan
SKSerap Karaman
Serap Karaman
ZKZeynep Karakaş
Zeynep Karakaş
AÜAyşegül Ünüvar
Ayşegül Ünüvar
Objective: Prophylaxis is the gold standard in patients with severe hemophilia. In recent years, personalisation of prophylaxis treatment according to pharmacokinetic properties has been used in treatment. In this study, personalisation treatment experience based on the pharmacokinetic dosing tool my-PKfit results in pediatric and adult patients from three centers is shared. Material and Methods: myPKfit (www1.mypkfit.com) was used to evaluate pharmacokinetic parameters in hemophilia A patients receiving recombinant Factor VIII (Takeda Advate ®) prophylaxis. 75 samples in 34 patients (3 samples in 7 patients, 2 samples in 27 patients) were analysed for pharmacokinetic evaluation. Age, weight and baseline FVIII level of the patients were recorded. Pharmacokinetic curves were obtained after entering sampling times, factor dose and sample results. The annual bleeding rate (ABR) of the patients were evaluated before and after the changes made after the pharmacokinetic evaluation. Results: The median age of 34 patients with severe hemophilia A without inhibitors was 12.3±8.7 (1.5-37) years, and the mean weight was 40.0±22.0 (10-83) kg. All patients had a baseline FVIII level of less than or equal to 2 IU/dl. All patients were receiving primary or secondary/tertiary prophylaxis. The mean half-life of the factors of the patients was 9.6±1.4 (7.0-13.4) hours, and the mean time reached below 1 IU/dl was 48.9±11.2 (16.0-77.0) hours. Prophylactic factor therapy was changed in 17 patients after myPKfit, dose increased in 9 patients, the frequency increased in 6 patients, and both dose and frequency increased in 2 patients. With a mean follow-up period of 23.7 +16 (2-49) months, in 17 patients whose prophylaxis regimen was changed after the PK evaluation by myPkyfit, ABR was found to be significantly lower in the post-change period, compared to the last one year before the change of regimen (2.94 + 2.19 and 0.58 + 1.00 respectively) P: 0.028. Discussion: A pharmacokinetic study by the Bayesian method is an increasingly used method for personalised prophylaxis regimen. We believe that myPKfit is beneficial in providing effective and appropriate prophylaxis.

20 September 2021
Verified
Book
Open access
PDF file
EÖErman Öztürk
Erman Öztürk
NENİLGÜN EROĞLU
NİLGÜN EROĞLU
AAAyşenur Arslan
Ayşenur Arslan
BABerna Ateşağaoğlu
Berna Ateşağaoğlu
TÖToluy Özgümüş
Toluy Özgümüş
AEAli Eser
Ali Eser
Primer hemostazın ana yapı taşı olan trombositlerin hastalıkları; kanamadan, koagulasyona iki ayrı uçta uzanan ve spektrumu geniş bir klinik yelpazede görülen hastalıklardır. Trombosit olarak da adlandırılan plateletler, kemik iliğinde megakaryositlerinden sentezlenerek 7-10 gün kaldıkları dolaşıma salınır. Trombositopeni, periferik kandaki normal trombosit sayısı dağılımının 2.5. alt persentil değeri olan 150×109/L’nin altındaki trombosit sayısı olarak tanımlanmaktadır. Trombositopeni için değerlendirme ise, klinik pratikte görülen en yaygın sorunlardan biridir. Trombositopeni ise kendi içinde, asemptomatik-hafif mükokutanöz kanama bulgularından, intrakranial kanama gibi hayatı tehdit edici kanamalar şeklinde değişen kanama bulgularının gözlenebildiği, laboratuvar bulguları ile düzeyinin ve izole trombositopeni laboratuar bulguları ile ağırlığı hakkında bilgi sahibi olunan bir durumdur. Azalmış kemik iliği üretimi, artan tüketim, artan yıkım, dalak sekestrasyonu veya bu nedenlerin bir kombinasyonu olarak çok sayıda doğumsal ve edinsel trombositopeni nedeni vardır.